Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Asymchem Laboratories (Tianjin) Co., Ltd. Class H ( (HK:6821) ) just unveiled an announcement.
Asymchem Laboratories (Tianjin) Co., Ltd. has called its 2025 annual general meeting for 10 June 2026 in Tianjin, where shareholders will review the 2025 annual report, board work report, financial statements, profit distribution plan and auditors’ reappointments, as well as directors’ remuneration. The AGM agenda also includes approval of foreign exchange derivatives activities, a three-year shareholder dividend return plan for 2026–2028, and special mandates to issue additional A and H shares and to repurchase A shares, signaling ongoing capital management and potential adjustments to its financial and shareholder return strategies.
These resolutions collectively outline how the company plans to manage profits, dividends, risk from currency exposure and future fundraising or buybacks, giving investors clearer visibility on capital allocation and governance. The combination of routine reporting approvals and fresh authorizations for equity issuance and repurchases may influence Asymchem’s funding flexibility, balance sheet structure and the returns available to shareholders over the coming years.
The most recent analyst rating on (HK:6821) stock is a Hold with a HK$120.00 price target. To see the full list of analyst forecasts on Asymchem Laboratories (Tianjin) Co., Ltd. Class H stock, see the HK:6821 Stock Forecast page.
More about Asymchem Laboratories (Tianjin) Co., Ltd. Class H
Asymchem Laboratories (Tianjin) Co., Ltd. is a joint stock company incorporated in the People’s Republic of China and listed in Hong Kong as a Class H share issuer. Operating in the pharmaceutical and biotechnology services sector, it provides contract research, development and manufacturing services that support drug development and commercialization for global clients.
Average Trading Volume: 558,380
Technical Sentiment Signal: Buy
Current Market Cap: HK$49.49B
See more insights into 6821 stock on TipRanks’ Stock Analysis page.